WNT5A and B-cell chronic lymphocytic leukemia: Two different studies showed that in CLL, WNT5A has been reported to contribute to resistance to the BTK inhibitor Ibrutinib [61] and the BCL-2 inhibitor Venetoclax [62], in both cases via a ROR1-dependent signaling axis [61,62].